Thanks guys.Telix Pharma (TLX AU): Raised to Buy at CLSA; PT AUD...

Thanks guys.

Telix Pharma (TLX AU): Raised to Buy at CLSA; PT AUD $7.90 (thanks @mnbvcxz12345)

Also Taylor Collison anticipated the right (exact!) sales for Q3 (USD $36m) back in July, with a valuation of AUD $9.30 based on this scenario.

http://www.taylorcollison.com.au/wp-content/uploads/2022/07/TLX-20220722-Illuccix-sales-update.pdf

22 July 2022

Telix reported sales for its Illuccix prostate cancer PET imaging agent in the US of US$13.6m in Q222.This was a positive surprise, 36% above our base case forecast and towards the upper end of our expected range of US$10-15m. While there is still a long way to go,Illuccix has made a strong start in the US and looks to be on track to capture 30% of the market, in line with our forecasts. With the Illuccix HCPCS reimbursement code and Pass-Through status in force since 1 July,we expect sales to grow by ~160% to US$36m in the current quarter;we increase forecast Illuccix scan volumes by 40% and 4% in 2022 and 2023, respectively.The upgraded near-term sales forecasts for Illuccix increase our valuation slightly to $9.77/sh (31-Mar $9.72), or $9.23/sh fully diluted.